Literature DB >> 9486650

HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C.

V M Braud1, D S Allan, C A O'Callaghan, K Söderström, A D'Andrea, G S Ogg, S Lazetic, N T Young, J I Bell, J H Phillips, L L Lanier, A J McMichael.   

Abstract

The protein HLA-E is a non-classical major histocompatibility complex (MHC) molecule of limited sequence variability. Its expression on the cell surface is regulated by the binding of peptides derived from the signal sequence of some other MHC class I molecules. Here we report the identification of ligands for HLA-E. We constructed tetramers in which recombinant HLA-E and beta2-microglobulin were refolded with an MHC leader-sequence peptide, biotinylated, and conjugated to phycoerythrin-labelled Extravidin. This HLA-E tetramer bound to natural killer (NK) cells and a small subset of T cells from peripheral blood. On transfectants, the tetramer bound to the CD94/NKG2A, CD94/NKGK2B and CD94/NKG2C NK cell receptors, but did not bind to the immunoglobulin family of NK cell receptors (KIR). Surface expression of HLA-E was enough to protect target cells from lysis by CD94/NKG2A+ NK-cell clones. A subset of HLA class I alleles has been shown to inhibit killing by CD94/NKG2A+ NK-cell clones. Only the HLA alleles that possess a leader peptide capable of upregulating HLA-E surface expression confer resistance to NK-cell-mediated lysis, implying that their action is mediated by HLA-E, the predominant ligand for the NK cell inhibitory receptor CD94/NKG2A.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9486650     DOI: 10.1038/35869

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  600 in total

Review 1.  Human gamma delta T lymphocytes in HIV disease: effector functions and control by natural killer cell receptors.

Authors:  M L Gougeon; F Poccia; S Boullier
Journal:  Springer Semin Immunopathol       Date:  2000

2.  Alloreactivity and association of human natural killer cells with the major histocompatibility complex.

Authors:  E Mavoungou; A Sall; V Poaty-Mavoungou; F S Toure; P Yaba; A Delicat; J Lansoud-Soukate
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

Review 3.  TAP deficiency syndrome.

Authors:  S D Gadola; H T Moins-Teisserenc; J Trowsdale; W L Gross; V Cerundolo
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

Review 4.  The major histocompatibility complex-encoded HFE in iron homeostasis and immune function.

Authors:  L Salter-Cid; P A Peterson; Y Yang
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

5.  The possible use of HLA-G1 and G3 in the inhibition of NK cell-mediated swine endothelial cell lysis.

Authors:  K Matsunami; S Miyagawa; R Nakai; A Murase; R Shirakura
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

6.  HLA-Cw7 zygosity affects the size of a subset of CD158b+ natural killer cells.

Authors:  Zaheed Husain; Edward Levitan; Charles E Larsen; Nadeem M Mirza; Souhad Younes; Edmond J Yunis; Chester A Alper; Devendra P Dubey
Journal:  J Clin Immunol       Date:  2002-01       Impact factor: 8.317

Review 7.  Development and use of multimeric major histocompatibility complex molecules.

Authors:  Tim F Greten; Jonathan P Schneck
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

8.  Function and subnuclear distribution of Rpp21, a protein subunit of the human ribonucleoprotein ribonuclease P.

Authors:  N Jarrous; R Reiner; D Wesolowski; H Mann; C Guerrier-Takada; S Altman
Journal:  RNA       Date:  2001-08       Impact factor: 4.942

9.  Ly49 genes in non-rodent mammals.

Authors:  Liane Gagnier; Brian T Wilhelm; Dixie L Mager
Journal:  Immunogenetics       Date:  2003-04-24       Impact factor: 2.846

Review 10.  IFN-gamma suspends the killing license of anti-tumor CTLs.

Authors:  Aron E Lukacher
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.